Grace Therapeutics (NASDAQ:GRCE) vs. Adhera Therapeutics (OTCMKTS:ATRX) Financial Review

Adhera Therapeutics (OTCMKTS:ATRX) and Grace Therapeutics (NASDAQ:GRCE) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, earnings, institutional ownership, profitability and dividends.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Adhera Therapeutics and Grace Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adhera Therapeutics	0	0	0	0	0.00
Grace Therapeutics	1	0	2	0	2.33

Grace Therapeutics has a consensus target price of $12.00, suggesting a potential upside of 214.14%. Given Grace Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Grace Therapeutics is more favorable than Adhera Therapeutics.

Insider and Institutional Ownership

6.1% of Grace Therapeutics shares are held by institutional investors. 28.2% of Adhera Therapeutics shares are held by company insiders. Comparatively, 11.1% of Grace Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Volatility & Risk

Adhera Therapeutics has a beta of 12.01, meaning that its stock price is 1,101% more volatile than the S&P 500. Comparatively, Grace Therapeutics has a beta of 0.55, meaning that its stock price is 45% less volatile than the S&P 500.

Profitability

This table compares Adhera Therapeutics and Grace Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Adhera Therapeutics	N/A	N/A	N/A
Grace Therapeutics	N/A	-17.47%	-15.89%

Valuation and Earnings

This table compares Adhera Therapeutics and Grace Therapeutics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adhera Therapeutics	N/A	N/A	N/A	($1.15)	N/A
Grace Therapeutics	N/A	N/A	-$9.57 million	($0.62)	-6.16

Grace Therapeutics is trading at a lower price-to-earnings ratio than Adhera Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Grace Therapeutics beats Adhera Therapeutics on 5 of the 9 factors compared between the two stocks.

About Adhera Therapeutics

Adhera Therapeutics, Inc., a biotech company, focuses on the discovery, development, and commercialization of small molecule drugs. The company is developing MLR-1019 for the treatment of Parkinson's disease; and MLR -1023 to treat Type 1 diabetes. The company was formerly known as Marina Biotech, Inc. and changed its name to Adhera Therapeutics, Inc. in October 2018. Adhera Therapeutics, Inc. is based in Baton Rouge, Louisiana.

About Grace Therapeutics

Grace Therapeutics Inc. is a late-stage biopharma company advancing GTx-104, its novel injectable formulation of nimodipine which addresses high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage. Grace Therapeutics Inc., formerly known as Acasti Pharma Inc., is based in Princeton, New Jersey.